PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 2001Hypertension105 citationsOpen Access

Workshop:Hypertension and Cardiovascular Risk Factors

View Full Paper
LRLeopoldo Raij

Structured PICO

P
Population
Patients with hypertension, diabetes, and atherosclerosis
I
Intervention
Therapeutic agents targeting the nitric oxide (NO)-angiotensin II axis
O
Outcome
Prevention of end-organ damage

Restoring the balance between nitric oxide and angiotensin II may be an effective therapeutic strategy to prevent end-organ damage in hypertension and cardiovascular disease.

Abstract

Vascular upregulation of nitric oxide (NO) is an adaptive response to increased blood pressure that may help in the prevention of end-organ damage. Differences in cardiovascular and renal morbidity and mortality in hypertensive patients may result, at least in part, from individual variations in endothelial function in response to the hemodynamic workload of hypertension. A functional feedback balance exists between both angiotensin (Ang) II and NO under normal conditions. The NO-Ang II imbalance may not explain all the vascular pathophysiology of hypertension, but it certainly appears to be an important component. In hypertension, salt sensitivity, whether primary (ie, certain populations in the United States and Japan) or secondary (ie, aging, type II diabetes), appears to be a marker of increased cardiovascular and renal risk that is often linked to a decreased bioactivity of NO. In diabetes and atherosclerosis, NO-dependent vascular relaxation is impaired and can be restored by decreasing the synthesis and/or blocking the action of Ang II. An understanding of the relations between hypertension, cardiovascular risk factors, end-organ damage, and the NO-Ang II axis leads one to believe that the combination of therapeutic agents capable of reinstating the homeostatic balance of these vasoactive molecules within the vessel wall would be most effective in preventing or arresting end-organ disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Leopoldo Raij (2001) studied this question.

synapsesocial.com/papers/6a718ca35d37378ac1deacbbhttps://doi.org/10.1161/01.hyp.37.2.767
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Significance of Nitric Oxide in Hypertension1994 · 5 citations
  2. 2Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension2006 · 92 citations
  3. 3The role of nitric oxide in the maintenance of vasoactive balance2007 · 62 citations
  4. 4Hypertension, nitric oxide and end-organ damage1999 · 4 citations
  5. 5NITRIC OXIDE, THE KIDNEY AND HYPERTENSION1997 · 30 citations